Trial Profile
A phase II study of carboplatin plus pemetrexed followed by gefitinib for stage IIIB/IV non-small cell lung cancer with EGFR mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2016
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Gefitinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2016 Interim results (n=29) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 19 Mar 2015 New trial record